Neoleukin Therapeutics Inc (NLTX)


Stock Price Forecast

Dec. 18, 2023


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Neoleukin Therapeutics Inc chart...

About the Company

neoleukin therapeutics, inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. the company's lead product candidate is nl-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (il)-2/il-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. the company was formerly known as aquinox pharmaceuticals, inc. and changed its name to neoleukin therapeutics, inc. in august 2019. neoleukin therapeutics, inc. was founded in 2003 and is headquartered in seattle, washington.

Exchange

NASDAQ

Website

neoleukin.com

$42M

Total Revenue

66

Employees

$31M

Market Capitalization

-4.19

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $NLTX News

Neoleukin Therapeutics, Inc. Common Stock (NLTX)

3y ago, source: Nasdaq

Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as a result, these ...

Neurogene (NGNE) Price Target Increased by 17.11% to 45.39

24d ago, source: Hosted on MSN

Neurogene Background Information (This description is provided by the company.) neoleukin therapeutics, inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation ...

Neoleukin Therapeutics Announces Third Quarter 2022 Financial Results and Corporate Update

1mon ago, source: ADVFN

Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced ...

Neoleukin Therapeutics Presents Preclinical Data on NEO-TRA1 at American Society of Hematology (ASH) Annual Meeting

1mon ago, source: ADVFN

Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today presented data ...

Ovid Therapeutics Inc OVID

12h ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Neurogene Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Updates

18h ago, source: Yahoo Finance

2024--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic ...

EFTR eFFECTOR Therapeutics, Inc.

4d ago, source: Seeking Alpha

eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product ...

Kintara Therapeutics Inc KTRA

16h ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Viking Therapeutics Inc.

19d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

G1 Therapeutics, Inc. (NASDAQ:GTHX) Q4 2023 Earnings Call Transcript

19d ago, source: Yahoo Finance

G1 Therapeutics, Inc. (NASDAQ:GTHX) Q4 2023 Earnings Call Transcript February 28, 2024 G1 Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.21, expectations were $-0.27.

ZVRA Zevra Therapeutics, Inc.

4d ago, source: Seeking Alpha

Zevra Therapeutics, Inc., a rare disease company melding science, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...